Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe Published on: 23/12/2016, Last update: 08/02/2017
The study will provide an economic evaluation of the incentives and rewards for pharmaceutical innovation in Europe, and its functioning within the Internal Market.
The study will, in particular, analyse the effects of supplementary protection certificates (SPCs) for pharmaceutical uses (human and veterinary), and plant protection, data protection and market exclusivity for medicinal products for human use.
Evidence on the overall impact on availability and accessibility of pharmaceutical care for patients and the pressure on health systems across the European Union will be examined. The evidence and analysis provided by this study will hence support the policy making in those areas.
Please note that since 1 January 2012, all tendering documents relating to DG GROW are published through a Commission wide unique platform called 'eTendering'. Consequently, the tendering documents are no longer published here.
If you are interested in this call, please access all the tender documents here.
The documents will always be visible and downloadable but if you ‘register’ to the call by adding your email address and a password, you will be able to ask questions and you will be automatically informed about all changes that may be published (additional documents, answers to questions, etc.).
Due to technical reasons the submission deadline is postponed until Thursday 9 February 2017 - 16:00